Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LymphoStat-B belimumab: Additional Phase II data

Data from 175 serologically active patients who completed 2.5 years (128 weeks) of treatment in an open-label extension of

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE